LobbyingVidrine Pharmaceutical Group, LLC D/B/A Boudreauxs New Drug Store lobbying by quarter
Vidrine Pharmaceutical Group, LLC D/B/A Boudreauxs New Drug Store's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $80K. Its first report covers Q4 2025; the issues it reports most are Pharmacy.
Vidrine Pharmaceutical Group, LLC D/B/A Boudreauxs New Drug Store
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $80K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $40K | 1 |
| Q1 2026 | $40K | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$80K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Food & Drug Administration (FDA)2 reports
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Buchanan Ingersoll & Rooney PC | $80K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| AMANDA LINCOLN | Staff Director, Senate Health, Education, Labor, and Pensions Committee; Legislative Director, Sen. Mike Enzi; Health Policy Director, Sen. Susan Collins | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 04/20for Q1 | Buchanan Ingersoll & Rooney PC | $40K |
| 01/20for Q4 2025 | Buchanan Ingersoll & Rooney PC | $40K |
| 25/11/11for Q4 2025 | Buchanan Ingersoll & Rooney PC | Under $5,000 |